Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice

This publication has 75 references indexed in Scilit:

• Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
  Nature, 2004
• Recombinant AAV Viral Vectors Pseudotyped with Viral Capsids from Serotypes 1, 2, and 5 Display Differential Efficiency and Cell Tropism after Delivery to Different Regions of the Central Nervous System
  Molecular Therapy, 2004
• RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
  Nature Medicine, 2004
• Inhibition of polyglutamine aggregate cytotoxicity by a structure‐based elongation inhibitor
  The FASEB Journal, 2004
• Loss of normal huntingtin function: new developments in Huntington's disease research
  Trends in Neurosciences, 2001
• Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield
  Gene Therapy, 1999
• Selective and Rapid Uptake of Adeno-Associated Virus Type 2 in Brain
  Human Gene Therapy, 1998
• Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion
  Nature Genetics, 1997
• Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice
  Cell, 1996
• Widespread expression of Huntington's disease gene (IT15) protein product
  Neuron, 1995